

Special Issue

Novel Advances in the Molecular Understanding of Myeloproliferative Neoplasms (MPNs)

Message from the Guest Editors

Myeloproliferative neoplasms (MPNs) encompass a diverse group of hematologic malignancies, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), as well as post-PV-MF and post-ET-MF. Progression to acute leukemia represents the most dreaded complication of the disease and a significant cause of mortality in MPN patients. This Special Issue aims to present the latest advances in exploring the molecular landscape of MPNs, offering a comprehensive overview of the role of molecular abnormalities in pathogenesis and discussing how these findings might guide treatments targeting vulnerabilities and reduce mutant allele burden in MPNs.

Guest Editors

Dr. Wei Chen

1. Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
2. Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China

Dr. Fei Li

The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, China

Dr. Qiang Jeremy Wen

St. Jude Children's Research Hospital, Memphis, TN, USA

Deadline for manuscript submissions

15 January 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/204797

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)